Study of adebrelimab, fuzuloparib, and chemo for resistant ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 70 years old.
- You must have ovarian, fallopian tube, or primary peritoneal cancer that came back within 6 months of your last platinum chemo.
- Your tumor must have a specific gene change (HRR gene mutation) found in a blood or tissue test.
- You must have at least one tumor that can be measured on a scan.
- You must be able to care for yourself (ECOG score 0 or 1) and have normal organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), a targeted therapy (bevacizumab), and a PARP inhibitor (fluzoparib) for ovarian cancer that came back at least 6 months after last platinum chemo. It aims to see if this mix helps control the cancer better.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
This trial tests a combination of three drugs (etoposide capsules, bevacizumab, and an immunotherapy pair) for ovarian cancer that no longer responds to standard platinum chemotherapy. It aims to find a new treatment option for women with resistant or refractory disease.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.